Clinical Trials on Plasma-Cell Myeloma

Total 35778 results

Institute of Hematology & Blood Diseases Hospital

Recruiting

National Longitudinal Cohort of Hematological Diseases (NICHE)

Lymphoma | Acute Myeloid Leukemia | Leukemia | Hemophilia A | Hemophilia B | Hemophilia | Multiple Myeloma | Myelodysplastic Syndrome | Bone Marrow Transplantation | MDS | Aplastic Anemia | Bleeding Disorder | Myeloma, Multiple | Myelomas, Multiple | Leukemias, Acute Myeloid | Myeloid Leukemias, Acute | Hemophilia As | Hemophilia... and other conditions

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Terminated

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Multiple Myeloma and Plasma Cell Neoplasm | Drug/Agent Toxicity by Tissue/Organ

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Neoplasms | Multiple Myeloma and Malignant Plasma Cell Neoplasms

United States
Wake Forest University Health Sciences

Completed

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation

Depression | Pain | Lymphoma | Myelodysplastic Syndromes | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Anxiety Disorder

United States
Asan Medical Center

Completed

Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

Lymphoma | Myelodysplastic Syndromes | Leukemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Nonmalignant Neoplasm

Korea, Republic of
California Cancer Consortium
National Cancer Institute (NCI)

Completed

Decitabine in Treating Patients With Melanoma or Other Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Fatigue | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Terminated

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease
Northwestern University

Completed

Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer

Lymphoma | Leukemia | Breast Cancer | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
NYU Langone Health
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition

United States
City of Hope Medical Center

Completed

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Smoldering Multiple Myeloma | Refractory Multiple Myeloma

United States
Pfizer

Active, not recruiting

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Lymphoma | Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Multiple Myeloma

United States
Jules Bordet Institute
RayzeBio, Inc.

Not yet recruiting

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors (AcTRESS)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Multiple Myeloma Progression

Belgium
Carl Ola Landgren, MD, PhD
Janssen Scientific Affairs, LLC

Recruiting

Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study) (REVIVE)

Multiple Myeloma

United States
Harpoon Therapeutics

Active, not recruiting

A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma of Bone

United States, France, Spain
Jagannath, Sundar, M.D.
Unicorn Pacific Corporation

Terminated

Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma

Multiple Myeloma

United States
University of Utah
Millennium Pharmaceuticals, Inc.

Terminated

Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients

Cancer | Multiple Myeloma | Myeloma

United States
Masonic Cancer Center, University of Minnesota

Terminated

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Secondary Myelofibrosis

United States
Masonic Cancer Center, University of Minnesota

Terminated

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI); Otsuka America Pharmaceutical

Completed

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen (LCCC0510)

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

MS-275 in Treating Patients With Hematologic Cancer

Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Smoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States
AbbVie

Active, not recruiting

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Acute Myeloid Leukemia | Cancer | Multiple Myeloma | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

United States, Australia, Canada, Denmark, Greece, Hong Kong, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Portugal, Russian Federation, Spain, Turkey, Ukraine, United Kingdom, France, Taiwan, Austria, Belgium, Ireland, S...
University of Texas Southwestern Medical Center

Completed

Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Withdrawn

Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myeloproliferative Disorders | Solid Tumor | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Nausea and Vomiting
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Neoplasms | Multiple Myeloma and Malignant Plasma Cell Neoplasms

United States
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
XuYan

Recruiting

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Dong-A University Hospital
Amgen

Not yet recruiting

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Dana-Farber Cancer Institute
National Institutes of Health (NIH); Genus Oncology, LLC

Withdrawn

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States
The First Affiliated Hospital of Xiamen University

Recruiting

All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Oncotherapeutics

Not yet recruiting

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Dong-A University Hospital

Not yet recruiting

Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM (KMM-KCd)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Amsterdam UMC, location VUmc

Not yet recruiting

Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study (POMAlternative)

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Luminary Therapeutics
The Cleveland Clinic; Case Western Reserve University

Recruiting

LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Tel-Aviv Sourasky Medical Center
Weizmann Institute of Science

Recruiting

Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

Israel
Tel-Aviv Sourasky Medical Center

Recruiting

Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib (IPoD-790)

Refractory Multiple Myeloma | Multiple Myeloma in Relapse

Israel
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
TJ Biopharma Co., Ltd.

Active, not recruiting

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Multiple Myeloma in Relapse

China, Taiwan
TJ Biopharma Co., Ltd.

Active, not recruiting

TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Multiple Myeloma in Relapse

China, Taiwan
Alliance Foundation Trials, LLC.
Pharmacyclics LLC.

Active, not recruiting

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States
National Cancer Institute (NCI)

Terminated

Aflibercept for Relapsed Multiple Myeloma

Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
Ajai Chari
Celgene Corporation

Completed

Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States

Clinical Trials on Plasma-Cell Myeloma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations